Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Withdrawal Friendly Total Market Etf Retirement
This guide covers withdrawal-friendly total market ETFs and how to structure distributions to maximize cash flow while controlling taxes in retirement.
28,154 articles
Current Price March 2026 Stabilizes as Oil Reaches New Peak
Oil prices pressed higher on March 26, 2026, nearing the mid-$100s per barrel. The move highlights how current price ...
Fubo Stock Finally Ready: Is It Time to Buy for 2026?
FuboTV has endured a brutal stretch as it tries to monetize a changing sports-media world. This deep dive weighs whet...
Reynolds (REYN) 2026 Earnings Outlook for Investors
As Reynolds prepares to report its 2026 earnings, investors are weighing growth catalysts, margin resilience, and pot...
Anthropic’s SpaceX Compute Deal Roils AI Data Center Market
Anthropic’s spacex compute deal expands access to the Colossus supercomputer, boosting Claude capacity while triggeri...
Iren Jumps $3.4 Billion on NVIDIA AI Cloud Deal, Shares Rally
IREN leaps on a landmark NVIDIA AI Cloud contract and a parallel equity option, signaling a strategic pivot from cryp...
Ted Turner Legacy: I Lost More Money and Market Lessons
As markets swing in 2026, investors revisit Ted Turner's risk-taking era, drawing lessons on diversification, leverag...
Celsius: From Highs, Stock - Is It a Buy Right Now?
Celsius shares have fallen more than 50% from their intraday peaks as growth from newly acquired brands accelerates. ...
Leading with Purpose: Teresa Shapes Housing Inclusion
Teresa Palacios Smith leads a broad push to embed inclusion into everyday operations at HomeServices of America, tur...
CAAP 2026 Earnings Call: What Investors Should Know
The CAAP 2026 earnings call offers more than quarterly results. This guide breaks down revenue drivers, margins, and ...
Rivian Faces Biggest Short-Term Threat: What Investors Need to Know
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
Erasca Stock 715%. Here’s Why One Biotech Fund Still Bets More
A major biotech fund boosted its Erasca stake after a monumental rise. This article unpacks the logic, risks, and tak...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status